Millendo Therapeutics Inc. Common Stock
(NASDAQ:MLND)
Description
Millendo Therapeutics, Inc., a biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company was incorporated in 2011 and is headquartered in Ann Arbor, Michigan.
MLND Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$2.0700 |
Previous Close Volume |
277028 |